{"ticker": {"uuid": "c7bd56e1-cc08-409e-9ea7-b35b85aad0e6", "symbol": "AKTS", "name": "Aktis Oncology, Inc. Common stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?", "summary": "Aktis Oncology (AKTS) stock has recently fallen by 16.3%, but current valuations still lean towards expensive rather than undervalued, passing only 2 of 6 valuation tests. The company's P/B ratio of 2.6x is in line with the biotech industry average, suggesting it's roughly fairly", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/has-aktis-oncology-akts-fallen-far-enough-to-be-below-fair-v", "source_name": "Simply Wall Street", "published_at": "2026-07-24T04:40:36", "published_display": "24 Jul 2026 04:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33", "summary": "Leerink Partners has initiated coverage on AKTIS Oncology Inc. with an Outperform rating. The firm has set a target price of $33 for the company's stock. This news comes from Reuters and reflects an analyst's opinion on the company's future performance.", "url": "https://www.bitget.com/amp/news/detail/12560605527434", "source_name": "Bitget", "published_at": "2026-07-22T18:11:31", "published_display": "22 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Inc : Leerink Partners Assumes", "summary": "This article states that Leerink Partners has initiated coverage on Aktis Oncology Inc. The content is very brief, serving primarily as an announcement of this new analyst coverage.", "url": "https://www.moomoo.com/news/flash/22835230/aktis-oncology-inc-leerink-partners-assumes-coverage-with-outperform-rating", "source_name": "Moomoo", "published_at": "2026-07-22T16:11:04", "published_display": "22 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving Average - Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNY09WZlhIWmNPb3ljV0ZwUV92VVFzbTBnNHI1ZmlkTzlWWjFGT3hqVFFVTi1DQ1p2a1pCYmZsM3ZTc3VhWlNPcmluSUgyOWdablBQRnlnMGpFSWdVM1g5Yi1xaW53dkMwV1RrN2lHNThWS19xWDl4TkFJbjRQbUlnWHRSdDVJNFVUWUFsQWs2MU9qcHhiTGtvQTN3a2hjYndZdjVkX0JJU2dlN0JFMnlISldxVG9ma3BtajRfaWlNTW5vakZkT0tqRG1R?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-22T08:43:16+00:00", "published_display": "22 Jul 2026 08:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Aktis Oncology Inc For: 21 July By Investing.com", "summary": "The article reports that Aktis Oncology Inc. filed a Form 4 for July 21. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. This filing indicates transactions in", "url": "https://ng.investing.com/news/stock-market-news/form-4-aktis-oncology-inc-for-21-july-93CH-2610212", "source_name": "Investing.com Nigeria", "published_at": "2026-07-22T01:41:53", "published_display": "22 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology director Ken Herrmann sells $119,274 in stock", "summary": "Aktis Oncology director Ken Herrmann sold 4,856 shares of common stock for $119,274 on July 20, 2026, after exercising fully vested stock options. This sale follows a period of strong stock performance for Aktis, which has seen its shares rise nearly 10% in the past six months. S", "url": "https://m.investing.com/news/insider-trading-news/aktis-oncology-director-ken-herrmann-sells-119274-in-stock-93CH-4804540?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-22T01:41:00", "published_display": "22 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78", "summary": "Aktis Oncology director Ken Herrmann sold 4,856 common shares on July 20, 2026, at $24.56 per share, totaling $119,256.78. He had acquired these shares previously through option exercises at much lower prices. Following these transactions, his direct common stock holding fell to ", "url": "https://www.bitget.com/amp/news/detail/12560605527005", "source_name": "Bitget", "published_at": "2026-07-22T00:41:00", "published_display": "22 Jul 2026 00:41", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (AKTS) director sells 4,856 shares after exercising options", "summary": "Aktis Oncology director Ken Herrmann exercised options for 4,856 shares at various strike prices and subsequently sold all those shares for approximately $119,000 gross proceeds. The transactions, which involved both execution of options and sale of common stock, were completed o", "url": "https://www.stocktitan.net/sec-filings/AKTS/form-4-aktis-oncology-inc-insider-trading-activity-6562cdef57fa.html", "source_name": "Stock Titan", "published_at": "2026-07-21T03:41:00", "published_display": "21 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akoustis Technologies (AKTS) insider plans 4,856-share stock sale after option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQbVJkeUpXa0EtallOamRTQV9VSmZvU3pkdGxQd1pNRE9lemhjYnZWdGlTeWpiNzhsY1J3N19KXzQtUlh2WVUtdkVBVU5KRVdqM0t0dkFtbFlkeTFxUV9rNk5LVTBkT3NKWXozU3gybHNYRTBMX1VlMklZNm1qT3YyV3BYV3EwWHU3aEhXLUR5ZDJPcHpXV3l3VlZLUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-20T20:52:19+00:00", "published_display": "20 Jul 2026 20:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise", "summary": "Ken Herrmann, a director at Aktis Oncology, Inc. (AKTS), executed a same-day option exercise and sale. He exercised 3,065 stock options at $0.08 per share and immediately sold these 3,065 shares at a weighted average price of $25.2067. After the transaction, Herrmann retains 3,50", "url": "https://www.stocktitan.net/sec-filings/AKTS/form-4-aktis-oncology-inc-insider-trading-activity-538a1390f7de.html", "source_name": "Stock Titan", "published_at": "2026-07-20T21:11:25", "published_display": "20 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTS Options Chain \u2014 NASDAQ:AKTS", "summary": "This page provides an options chain for Aktis Oncology, Inc. (AKTS) on the Nasdaq Stock Market. It allows users to monitor live pricing, Greeks, implied volatility, and other key metrics for available call and put options contracts. The platform emphasizes evaluating market movem", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/options-chain/", "source_name": "TradingView", "published_at": "2026-07-20T12:10:04", "published_display": "20 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "This article provides \"Enterprise value to revenue forward\" data for Aktis Oncology, Inc. (NASDAQ: AKTS) on TradingView. The content indicates a period, a value, and change percentages, noting that the data was \"Made by humans.\"", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-20T03:11:25", "published_display": "20 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "The article focuses on the enterprise value to EBIT forward ratio for Aktis Oncology, Inc. (NASDAQ: AKTS). It appears to be a financial data page from TradingView, providing an overview of a specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T17:40:52", "published_display": "19 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for Aktis Oncology, specifically for July 17. The content provided is minimal, essentially just stating the filing and date without furnishing any details about the filing itself. The majority of the page consists of we", "url": "https://ng.investing.com/news/stock-market-news/form-144-aktis-oncology-for-17-july-93CH-2605878", "source_name": "Investing.com Nigeria", "published_at": "2026-07-19T02:40:52", "published_display": "19 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology, Inc. SEC Filing (Jul 17, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPNmZDblVuUzQzNmVPOEJKV3dGTUJEdFdFNUhEbllNVEloUE9BN2JhS2hMeEVKaW5ZVVc1cjlUUWRrYlNqVFZNTUhyN0o3dG9ldG5CNzlMZlZ6Mmh2UWt3SjktcTZkVUVzWTN2VVBjTkZ1WXNwQy1wTDN2YkJIMUJlYW02dmJwRUJRd3lnUjZheFd4MnR2dWdFQ2pzaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:27:11+00:00", "published_display": "17 Jul 2026 21:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Aktis Oncology, Inc. SEC Filing", "summary": "This article reports on an SEC Form 144 filing by Aktis Oncology, Inc. (AKTS) detailing a proposed sale of securities. The filing indicates a stock option exercise by an individual, with 3065 shares of common stock valued at $77,258.54 to be sold through Morgan Stanley Smith Barn", "url": "https://www.stocktitan.net/sec-filings/AKTS/144-aktis-oncology-inc-sec-filing-39de68869928.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:10:09", "published_display": "17 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTS Options Volatility \u2014 NASDAQ:AKTS", "summary": "This article provides an overview of Aktis Oncology, Inc. (AKTS) options volatility on TradingView. It highlights implied volatility curves and at-the-money (ATM) implied volatility across different expirations, offering tools for traders to assess market expectations and identif", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/options-volatility/", "source_name": "TradingView", "published_at": "2026-07-17T20:10:09", "published_display": "17 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "This page from TradingView provides financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically focusing on its forward price-to-sales ratio. It lists the company's financial data, news, and community sentiment within the platform's interface. The article itself d", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-17T14:10:48", "published_display": "17 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "New Options Listings Include Aktis Oncology Inc (AKTS)", "summary": "Aktis Oncology Inc (AKTS) has been added to new options listings, reflecting a growing interest in diverse investment opportunities in the biotechnology sector. Despite this, AKTS has a low GF Score\u2122 of 9/100 and a high price-to-sales ratio, indicating significant future growth e", "url": "https://www.gurufocus.com/news/8959978/new-options-listings-include-aktis-oncology-inc-akts?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T13:15:11", "published_display": "15 Jul 2026 13:15", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $33", "summary": "J.P. Morgan has reiterated its Buy rating on Aktis Oncology (AKTS.US), indicating continued confidence in the company's prospects. The firm also raised its target price for Aktis Oncology shares to $33, suggesting an increased positive outlook on the stock's future performance. T", "url": "https://www.moomoo.com/news/post/72937126/jp-morgan-maintains-aktis-oncology-aktsus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-15T02:10:09", "published_display": "15 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTS Maintained by JP Morgan -- Price Target Raised to $33.00", "summary": "JP Morgan has maintained an Overweight rating on Aktis Oncology (AKTS), increasing its price target from $30.00 to $33.00. This reflects growing confidence in the company's targeted radiopharmaceuticals, despite a low GF Score\u2122 of 9/100, which indicates potential financial and gr", "url": "https://www.gurufocus.com/news/8957932/akts-maintained-by-jp-morgan-price-target-raised-to-3300", "source_name": "GuruFocus", "published_at": "2026-07-14T15:11:32", "published_display": "14 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "This article provides key financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically its \"Price to book forward\" value. It indicates that the market was closed and no trades were made at the time of publication, with data provided by ICE Data Services and FactSet", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T00:12:12", "published_display": "14 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "This article provides financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically its \"Price to earnings forward\" metric. The content points to data sourced from ICE Data Services and FactSet, and indicates the market for AKTS shares was closed with no trades at t", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T21:41:13", "published_display": "13 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$AKTS stock is down 12% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQMTB0SmV0SWp1UmlpRzNhTzFCZEp3RkJqMEZhVFZEMUFUc1h3aXpOWmkxTUpzckFRam51VGRUbFpfaUlCX3Nab2FUOC1Dbk53QmFNMWtTMi1TSkV3NEo5WEo3cjlmUDlhYnpIdUVVVHp6V254QXJTWEFSSVN2WHhuNzA4RUFBeDdJVTRzT3VMVTgxV0dRQ0tCem9oTThRXzM0YUpz?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing", "summary": "An insider at Aktis Oncology recently sold shares valued at $1,387,558, as detailed in a recent SEC filing. This transaction involved the sale of both common stock and options.", "url": "https://www.moomoo.com/news/post/72777636/aktis-oncology-insider-sold-shares-worth-1387558-according-to-a", "source_name": "Moomoo", "published_at": "2026-07-11T00:10:59", "published_display": "11 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Aktis Oncology Inc For: 10 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Aktis Oncology Inc. for July 10. It is a brief report providing information on insider transactions for the company (AKTS).", "url": "https://ng.investing.com/news/stock-market-news/form-4-aktis-oncology-inc-for-10-july-93CH-2594613", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T11:40:29", "published_display": "10 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/aktis-oncology-insider-sold-shares-102625940.html", "source_name": "MT Newswires", "published_at": "2026-07-10T10:26:25+00:00", "published_display": "10 Jul 2026 10:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology COO Ron-Bigger sells $1.39m in shares By Investing.com", "summary": "Aktis Oncology's Chief Operating Officer, Ron-Bigger Shulamit, sold approximately $1.39 million worth of company shares on July 8, 2026. The transaction involved exercising stock options and then immediately selling the acquired 50,000 shares, which had a vesting schedule startin", "url": "https://ca.investing.com/news/stock-market-news/aktis-oncology-coo-ronbigger-sells-139m-in-shares-93CH-4728844", "source_name": "Investing.com Canada", "published_at": "2026-07-10T10:22:41", "published_display": "10 Jul 2026 10:22", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Insiders Sold Shares Worth Over $2.8M", "summary": "Two key officers at Aktis Oncology, Chief Medical Officer Czibere Akos and Chief Operating Officer Ron-Bigger Shulamit, sold significant amounts of common stock on July 8, 2026. Each officer sold shares totaling over $1.3 million, and following these transactions, neither directl", "url": "https://www.tradingview.com/news/tradingview:addb2ccdcbe0a:0-aktis-oncology-insiders-sold-shares-worth-over-2-8m/", "source_name": "TradingView", "published_at": "2026-07-10T10:19:41", "published_display": "10 Jul 2026 10:19", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares", "summary": "Aktis Oncology's Chief Operating Officer, Shulamit Ron-Bigger, exercised 50,000 stock options at $3.66 per share and simultaneously sold 50,000 common shares in open-market transactions on July 8, 2026. The sales occurred at weighted average prices in the high-$20s per share. Fol", "url": "https://www.stocktitan.net/sec-filings/AKTS/form-4-aktis-oncology-inc-insider-trading-activity-c323d16e376e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T10:12:41", "published_display": "10 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades", "summary": "Aktis Oncology's Chief Medical Officer, Akos Czibere, executed an exercise-and-sell transaction on July 8, 2026. He exercised 50,000 stock options at $4.95 per share and subsequently sold all 50,000 acquired shares in multiple open-market transactions at weighted average prices i", "url": "https://www.stocktitan.net/sec-filings/AKTS/form-4-aktis-oncology-inc-insider-trading-activity-242335d2dcc5.html", "source_name": "Stock Titan", "published_at": "2026-07-10T10:12:41", "published_display": "10 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology, Inc. SEC Filing", "summary": "Aktis Oncology, Inc. (AKTS) has filed a Form 144 with the SEC, indicating a proposed sale of 50,000 shares of common stock with an aggregate market value of $1,388,700. The securities were acquired on July 8, 2026, through an exercise of options under a registered plan, with paym", "url": "https://www.stocktitan.net/sec-filings/AKTS/144-aktis-oncology-inc-sec-filing-67db79fc2fa2.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:11:16", "published_display": "08 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Options of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.", "summary": "Aktis Oncology, Inc. has certain options subject to a lock-up agreement that ends on July 8, 2026. This agreement, which began on January 8, 2026, prevents company directors, executive officers, and major shareholders from selling or transferring common stock or convertible secur", "url": "https://www.marketscreener.com/news/certain-options-of-aktis-oncology-inc-are-subject-to-a-lock-up-agreement-ending-on-8-jul-2026-ce7f5ed8df8af420", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T23:10:42", "published_display": "07 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "34,872,279 Common Stock of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.", "summary": "This article announces that 34,872,279 common stock shares of Aktis Oncology, Inc. are subject to a lock-up agreement, which began on January 8, 2026, and will end on July 8, 2026. This lock-up prevents company directors, executive officers, and substantial shareholders from sell", "url": "https://www.marketscreener.com/news/34-872-279-common-stock-of-aktis-oncology-inc-are-subject-to-a-lock-up-agreement-ending-on-8-jul-2-ce7f5ed8df8af427", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T20:23:00", "published_display": "07 Jul 2026 20:23", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology, Inc. Actuals & Estimates (NASDAQ:AKTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNT0xqWVZFOTJOVHhBMEh3Z2Qya3FlWlFUMzBxaV9mdjRxdFRHU293ekd6MkxUN1B6VHhnSE9vVlYydzQ4YkwzMXBWa3JlTVpxZklKSTZ3NXNvNmdMdDQ1TmNhYzF5YXZsdEsxZHZWYTVJWkVXMVczOXFNN1otM2N5NjRUY2JEdw?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T18:16:34+00:00", "published_display": "25 Jun 2026 18:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/raymond-james-initiates-aktis-oncology-091930619.html", "source_name": "MT Newswires", "published_at": "2026-06-16T09:19:30+00:00", "published_display": "16 Jun 2026 09:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQTE1nanpPd3ViMzY1eFhOMTdtNmRUS2xPUWZEZVBYa3Z0S0pwbm1UOHM5YVAzN3ljVE13V1hCME9kRGc2Tk5xNjRIUWdnRzE1d2Y5b3dNQXA4ZFViSVVsZnpwT3IwSm43eFJad3hRQllSNENxS0xoU2FPZFd3R0s3ZWlRVW1Wel9Vd0dOUVhR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology to Present at the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aktis-oncology-present-jefferies-global-200500003.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T20:05:00+00:00", "published_display": "27 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPOUFkSy1nX3Y3VnBkYllvV0Q5aGZ0cEQ4eWtnSUdCSXRJRXBQWEdBaUpHUGE3MGpodWZHY25GdkxxbWlrV281T3ZNYmozNFptSktYYnpXWlJoNGpTS09yWEdhWUJrY1BJb1JzYlIzMkNWRFQ5djVjRzE3M0JMQ2JzUlpPX1RSYjNmQkkwWmdURDE2UHhYM2c0cjNzWmpwUXRw?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aktis-oncology-reports-first-human-212100787.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:21:00+00:00", "published_display": "21 May 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aktis: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aktis-q1-earnings-snapshot-205645439.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:56:45+00:00", "published_display": "11 May 2026 20:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aktis-oncology-reports-financial-results-200100514.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:01:00+00:00", "published_display": "11 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer radiopharma firm Aktis adds $365M IPO cash, funds to 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeDBrb0lWRHZJbVZ0eE1yMWlvS3BmNUlSbU5SZktnTmtjVmgxX2RHUnBPV0ZJNE5lemc0Nm43WEd2SjRESHRzclluaEdwMU8xbEV2aEVNUVdXQkstcVRoWmJJdmdWeFhrYVlnNmRlVXUzREt4Z1FZaEdELXFLekoyVi1Db0NxVzB6eGVBV182VkRBYl9BRFdvdWt2R2VwX0lmWjZGUTRReE9oQVJaWGI0NUx3VlNfVnNWWUpUdUFOcTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOeEc0UzI4cVNPMm9OMi1UQ2o0M214NmYwZDZCUEpnR2xtTTkyVXJhYk5qYTcwemdHZ2Y5M3lxNEFESGNtMEh1TVF0U0xCcVNtVmlXc3RXOVNwOWNvS2FraHVLOGhEbk93LWpwUWZKN0VBby1lOWRNR0R3dHdlYndaSWxJb0NaV19VSkU4QzU3eDNsOUhCQ1h0THhXMmhweHhMdGc?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxONDFUU01fLTEwb0Y1N2d1M3ZTUldYOXFVQ3lKQkd5cFo4UWdpd2k0aXQzV1k2emxpXzdMZU9BS3dqSDVuS2gzbzhFbWlZNFpSMTZCdXQ3YVJHM05QYVFaUk5XSmpjUXVzREJ2TnA5dFpaUzhtRzZxOEo3MVZ3bS1ldHVVVE5zTFhJekdsN0t3?oc=5", "source_name": "Market source", "published_at": "2026-01-18T08:00:00+00:00", "published_display": "18 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?", "summary": "Aktis Oncology (AKTS) stock has recently fallen by 16.3%, but current valuations still lean towards expensive rather than undervalued, passing only 2 of 6 valuation tests. The company's P/B ratio of 2.6x is in line with the biotech industry average, suggesting it's roughly fairly", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/has-aktis-oncology-akts-fallen-far-enough-to-be-below-fair-v", "source_name": "Simply Wall Street", "published_at": "2026-07-24T04:40:36", "published_display": "24 Jul 2026 04:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33", "summary": "Leerink Partners has initiated coverage on AKTIS Oncology Inc. with an Outperform rating. The firm has set a target price of $33 for the company's stock. This news comes from Reuters and reflects an analyst's opinion on the company's future performance.", "url": "https://www.bitget.com/amp/news/detail/12560605527434", "source_name": "Bitget", "published_at": "2026-07-22T18:11:31", "published_display": "22 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Inc : Leerink Partners Assumes", "summary": "This article states that Leerink Partners has initiated coverage on Aktis Oncology Inc. The content is very brief, serving primarily as an announcement of this new analyst coverage.", "url": "https://www.moomoo.com/news/flash/22835230/aktis-oncology-inc-leerink-partners-assumes-coverage-with-outperform-rating", "source_name": "Moomoo", "published_at": "2026-07-22T16:11:04", "published_display": "22 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving Average - Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNY09WZlhIWmNPb3ljV0ZwUV92VVFzbTBnNHI1ZmlkTzlWWjFGT3hqVFFVTi1DQ1p2a1pCYmZsM3ZTc3VhWlNPcmluSUgyOWdablBQRnlnMGpFSWdVM1g5Yi1xaW53dkMwV1RrN2lHNThWS19xWDl4TkFJbjRQbUlnWHRSdDVJNFVUWUFsQWs2MU9qcHhiTGtvQTN3a2hjYndZdjVkX0JJU2dlN0JFMnlISldxVG9ma3BtajRfaWlNTW5vakZkT0tqRG1R?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-22T08:43:16+00:00", "published_display": "22 Jul 2026 08:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Aktis Oncology Inc For: 21 July By Investing.com", "summary": "The article reports that Aktis Oncology Inc. filed a Form 4 for July 21. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. This filing indicates transactions in", "url": "https://ng.investing.com/news/stock-market-news/form-4-aktis-oncology-inc-for-21-july-93CH-2610212", "source_name": "Investing.com Nigeria", "published_at": "2026-07-22T01:41:53", "published_display": "22 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology director Ken Herrmann sells $119,274 in stock", "summary": "Aktis Oncology director Ken Herrmann sold 4,856 shares of common stock for $119,274 on July 20, 2026, after exercising fully vested stock options. This sale follows a period of strong stock performance for Aktis, which has seen its shares rise nearly 10% in the past six months. S", "url": "https://m.investing.com/news/insider-trading-news/aktis-oncology-director-ken-herrmann-sells-119274-in-stock-93CH-4804540?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-22T01:41:00", "published_display": "22 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78", "summary": "Aktis Oncology director Ken Herrmann sold 4,856 common shares on July 20, 2026, at $24.56 per share, totaling $119,256.78. He had acquired these shares previously through option exercises at much lower prices. Following these transactions, his direct common stock holding fell to ", "url": "https://www.bitget.com/amp/news/detail/12560605527005", "source_name": "Bitget", "published_at": "2026-07-22T00:41:00", "published_display": "22 Jul 2026 00:41", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (AKTS) director sells 4,856 shares after exercising options", "summary": "Aktis Oncology director Ken Herrmann exercised options for 4,856 shares at various strike prices and subsequently sold all those shares for approximately $119,000 gross proceeds. The transactions, which involved both execution of options and sale of common stock, were completed o", "url": "https://www.stocktitan.net/sec-filings/AKTS/form-4-aktis-oncology-inc-insider-trading-activity-6562cdef57fa.html", "source_name": "Stock Titan", "published_at": "2026-07-21T03:41:00", "published_display": "21 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akoustis Technologies (AKTS) insider plans 4,856-share stock sale after option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQbVJkeUpXa0EtallOamRTQV9VSmZvU3pkdGxQd1pNRE9lemhjYnZWdGlTeWpiNzhsY1J3N19KXzQtUlh2WVUtdkVBVU5KRVdqM0t0dkFtbFlkeTFxUV9rNk5LVTBkT3NKWXozU3gybHNYRTBMX1VlMklZNm1qT3YyV3BYV3EwWHU3aEhXLUR5ZDJPcHpXV3l3VlZLUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-20T20:52:19+00:00", "published_display": "20 Jul 2026 20:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise", "summary": "Ken Herrmann, a director at Aktis Oncology, Inc. (AKTS), executed a same-day option exercise and sale. He exercised 3,065 stock options at $0.08 per share and immediately sold these 3,065 shares at a weighted average price of $25.2067. After the transaction, Herrmann retains 3,50", "url": "https://www.stocktitan.net/sec-filings/AKTS/form-4-aktis-oncology-inc-insider-trading-activity-538a1390f7de.html", "source_name": "Stock Titan", "published_at": "2026-07-20T21:11:25", "published_display": "20 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTS Options Chain \u2014 NASDAQ:AKTS", "summary": "This page provides an options chain for Aktis Oncology, Inc. (AKTS) on the Nasdaq Stock Market. It allows users to monitor live pricing, Greeks, implied volatility, and other key metrics for available call and put options contracts. The platform emphasizes evaluating market movem", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/options-chain/", "source_name": "TradingView", "published_at": "2026-07-20T12:10:04", "published_display": "20 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "This article provides \"Enterprise value to revenue forward\" data for Aktis Oncology, Inc. (NASDAQ: AKTS) on TradingView. The content indicates a period, a value, and change percentages, noting that the data was \"Made by humans.\"", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-20T03:11:25", "published_display": "20 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "The article focuses on the enterprise value to EBIT forward ratio for Aktis Oncology, Inc. (NASDAQ: AKTS). It appears to be a financial data page from TradingView, providing an overview of a specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T17:40:52", "published_display": "19 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for Aktis Oncology, specifically for July 17. The content provided is minimal, essentially just stating the filing and date without furnishing any details about the filing itself. The majority of the page consists of we", "url": "https://ng.investing.com/news/stock-market-news/form-144-aktis-oncology-for-17-july-93CH-2605878", "source_name": "Investing.com Nigeria", "published_at": "2026-07-19T02:40:52", "published_display": "19 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology, Inc. SEC Filing (Jul 17, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPNmZDblVuUzQzNmVPOEJKV3dGTUJEdFdFNUhEbllNVEloUE9BN2JhS2hMeEVKaW5ZVVc1cjlUUWRrYlNqVFZNTUhyN0o3dG9ldG5CNzlMZlZ6Mmh2UWt3SjktcTZkVUVzWTN2VVBjTkZ1WXNwQy1wTDN2YkJIMUJlYW02dmJwRUJRd3lnUjZheFd4MnR2dWdFQ2pzaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:27:11+00:00", "published_display": "17 Jul 2026 21:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Aktis Oncology, Inc. SEC Filing", "summary": "This article reports on an SEC Form 144 filing by Aktis Oncology, Inc. (AKTS) detailing a proposed sale of securities. The filing indicates a stock option exercise by an individual, with 3065 shares of common stock valued at $77,258.54 to be sold through Morgan Stanley Smith Barn", "url": "https://www.stocktitan.net/sec-filings/AKTS/144-aktis-oncology-inc-sec-filing-39de68869928.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:10:09", "published_display": "17 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTS Options Volatility \u2014 NASDAQ:AKTS", "summary": "This article provides an overview of Aktis Oncology, Inc. (AKTS) options volatility on TradingView. It highlights implied volatility curves and at-the-money (ATM) implied volatility across different expirations, offering tools for traders to assess market expectations and identif", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/options-volatility/", "source_name": "TradingView", "published_at": "2026-07-17T20:10:09", "published_display": "17 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "This page from TradingView provides financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically focusing on its forward price-to-sales ratio. It lists the company's financial data, news, and community sentiment within the platform's interface. The article itself d", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-17T14:10:48", "published_display": "17 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Options Listings Include Aktis Oncology Inc (AKTS)", "summary": "Aktis Oncology Inc (AKTS) has been added to new options listings, reflecting a growing interest in diverse investment opportunities in the biotechnology sector. Despite this, AKTS has a low GF Score\u2122 of 9/100 and a high price-to-sales ratio, indicating significant future growth e", "url": "https://www.gurufocus.com/news/8959978/new-options-listings-include-aktis-oncology-inc-akts?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T13:15:11", "published_display": "15 Jul 2026 13:15", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $33", "summary": "J.P. Morgan has reiterated its Buy rating on Aktis Oncology (AKTS.US), indicating continued confidence in the company's prospects. The firm also raised its target price for Aktis Oncology shares to $33, suggesting an increased positive outlook on the stock's future performance. T", "url": "https://www.moomoo.com/news/post/72937126/jp-morgan-maintains-aktis-oncology-aktsus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-15T02:10:09", "published_display": "15 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTS Maintained by JP Morgan -- Price Target Raised to $33.00", "summary": "JP Morgan has maintained an Overweight rating on Aktis Oncology (AKTS), increasing its price target from $30.00 to $33.00. This reflects growing confidence in the company's targeted radiopharmaceuticals, despite a low GF Score\u2122 of 9/100, which indicates potential financial and gr", "url": "https://www.gurufocus.com/news/8957932/akts-maintained-by-jp-morgan-price-target-raised-to-3300", "source_name": "GuruFocus", "published_at": "2026-07-14T15:11:32", "published_display": "14 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "This article provides key financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically its \"Price to book forward\" value. It indicates that the market was closed and no trades were made at the time of publication, with data provided by ICE Data Services and FactSet", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T00:12:12", "published_display": "14 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aktis Oncology, Inc. \u2013 NASDAQ:AKTS", "summary": "This article provides financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically its \"Price to earnings forward\" metric. The content points to data sourced from ICE Data Services and FactSet, and indicates the market for AKTS shares was closed with no trades at t", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T21:41:13", "published_display": "13 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$AKTS stock is down 12% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQMTB0SmV0SWp1UmlpRzNhTzFCZEp3RkJqMEZhVFZEMUFUc1h3aXpOWmkxTUpzckFRam51VGRUbFpfaUlCX3Nab2FUOC1Dbk53QmFNMWtTMi1TSkV3NEo5WEo3cjlmUDlhYnpIdUVVVHp6V254QXJTWEFSSVN2WHhuNzA4RUFBeDdJVTRzT3VMVTgxV0dRQ0tCem9oTThRXzM0YUpz?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing", "summary": "An insider at Aktis Oncology recently sold shares valued at $1,387,558, as detailed in a recent SEC filing. This transaction involved the sale of both common stock and options.", "url": "https://www.moomoo.com/news/post/72777636/aktis-oncology-insider-sold-shares-worth-1387558-according-to-a", "source_name": "Moomoo", "published_at": "2026-07-11T00:10:59", "published_display": "11 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Aktis Oncology Inc For: 10 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Aktis Oncology Inc. for July 10. It is a brief report providing information on insider transactions for the company (AKTS).", "url": "https://ng.investing.com/news/stock-market-news/form-4-aktis-oncology-inc-for-10-july-93CH-2594613", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T11:40:29", "published_display": "10 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/aktis-oncology-insider-sold-shares-102625940.html", "source_name": "MT Newswires", "published_at": "2026-07-10T10:26:25+00:00", "published_display": "10 Jul 2026 10:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology COO Ron-Bigger sells $1.39m in shares By Investing.com", "summary": "Aktis Oncology's Chief Operating Officer, Ron-Bigger Shulamit, sold approximately $1.39 million worth of company shares on July 8, 2026. The transaction involved exercising stock options and then immediately selling the acquired 50,000 shares, which had a vesting schedule startin", "url": "https://ca.investing.com/news/stock-market-news/aktis-oncology-coo-ronbigger-sells-139m-in-shares-93CH-4728844", "source_name": "Investing.com Canada", "published_at": "2026-07-10T10:22:41", "published_display": "10 Jul 2026 10:22", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Insiders Sold Shares Worth Over $2.8M", "summary": "Two key officers at Aktis Oncology, Chief Medical Officer Czibere Akos and Chief Operating Officer Ron-Bigger Shulamit, sold significant amounts of common stock on July 8, 2026. Each officer sold shares totaling over $1.3 million, and following these transactions, neither directl", "url": "https://www.tradingview.com/news/tradingview:addb2ccdcbe0a:0-aktis-oncology-insiders-sold-shares-worth-over-2-8m/", "source_name": "TradingView", "published_at": "2026-07-10T10:19:41", "published_display": "10 Jul 2026 10:19", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares", "summary": "Aktis Oncology's Chief Operating Officer, Shulamit Ron-Bigger, exercised 50,000 stock options at $3.66 per share and simultaneously sold 50,000 common shares in open-market transactions on July 8, 2026. The sales occurred at weighted average prices in the high-$20s per share. Fol", "url": "https://www.stocktitan.net/sec-filings/AKTS/form-4-aktis-oncology-inc-insider-trading-activity-c323d16e376e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T10:12:41", "published_display": "10 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades", "summary": "Aktis Oncology's Chief Medical Officer, Akos Czibere, executed an exercise-and-sell transaction on July 8, 2026. He exercised 50,000 stock options at $4.95 per share and subsequently sold all 50,000 acquired shares in multiple open-market transactions at weighted average prices i", "url": "https://www.stocktitan.net/sec-filings/AKTS/form-4-aktis-oncology-inc-insider-trading-activity-242335d2dcc5.html", "source_name": "Stock Titan", "published_at": "2026-07-10T10:12:41", "published_display": "10 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology, Inc. SEC Filing", "summary": "Aktis Oncology, Inc. (AKTS) has filed a Form 144 with the SEC, indicating a proposed sale of 50,000 shares of common stock with an aggregate market value of $1,388,700. The securities were acquired on July 8, 2026, through an exercise of options under a registered plan, with paym", "url": "https://www.stocktitan.net/sec-filings/AKTS/144-aktis-oncology-inc-sec-filing-67db79fc2fa2.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:11:16", "published_display": "08 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Options of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.", "summary": "Aktis Oncology, Inc. has certain options subject to a lock-up agreement that ends on July 8, 2026. This agreement, which began on January 8, 2026, prevents company directors, executive officers, and major shareholders from selling or transferring common stock or convertible secur", "url": "https://www.marketscreener.com/news/certain-options-of-aktis-oncology-inc-are-subject-to-a-lock-up-agreement-ending-on-8-jul-2026-ce7f5ed8df8af420", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T23:10:42", "published_display": "07 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "34,872,279 Common Stock of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.", "summary": "This article announces that 34,872,279 common stock shares of Aktis Oncology, Inc. are subject to a lock-up agreement, which began on January 8, 2026, and will end on July 8, 2026. This lock-up prevents company directors, executive officers, and substantial shareholders from sell", "url": "https://www.marketscreener.com/news/34-872-279-common-stock-of-aktis-oncology-inc-are-subject-to-a-lock-up-agreement-ending-on-8-jul-2-ce7f5ed8df8af427", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T20:23:00", "published_display": "07 Jul 2026 20:23", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology, Inc. Actuals & Estimates (NASDAQ:AKTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNT0xqWVZFOTJOVHhBMEh3Z2Qya3FlWlFUMzBxaV9mdjRxdFRHU293ekd6MkxUN1B6VHhnSE9vVlYydzQ4YkwzMXBWa3JlTVpxZklKSTZ3NXNvNmdMdDQ1TmNhYzF5YXZsdEsxZHZWYTVJWkVXMVczOXFNN1otM2N5NjRUY2JEdw?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T18:16:34+00:00", "published_display": "25 Jun 2026 18:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/raymond-james-initiates-aktis-oncology-091930619.html", "source_name": "MT Newswires", "published_at": "2026-06-16T09:19:30+00:00", "published_display": "16 Jun 2026 09:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQTE1nanpPd3ViMzY1eFhOMTdtNmRUS2xPUWZEZVBYa3Z0S0pwbm1UOHM5YVAzN3ljVE13V1hCME9kRGc2Tk5xNjRIUWdnRzE1d2Y5b3dNQXA4ZFViSVVsZnpwT3IwSm43eFJad3hRQllSNENxS0xoU2FPZFd3R0s3ZWlRVW1Wel9Vd0dOUVhR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology to Present at the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aktis-oncology-present-jefferies-global-200500003.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T20:05:00+00:00", "published_display": "27 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPOUFkSy1nX3Y3VnBkYllvV0Q5aGZ0cEQ4eWtnSUdCSXRJRXBQWEdBaUpHUGE3MGpodWZHY25GdkxxbWlrV281T3ZNYmozNFptSktYYnpXWlJoNGpTS09yWEdhWUJrY1BJb1JzYlIzMkNWRFQ5djVjRzE3M0JMQ2JzUlpPX1RSYjNmQkkwWmdURDE2UHhYM2c0cjNzWmpwUXRw?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aktis-oncology-reports-first-human-212100787.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:21:00+00:00", "published_display": "21 May 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aktis-q1-earnings-snapshot-205645439.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:56:45+00:00", "published_display": "11 May 2026 20:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aktis-oncology-reports-financial-results-200100514.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:01:00+00:00", "published_display": "11 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer radiopharma firm Aktis adds $365M IPO cash, funds to 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeDBrb0lWRHZJbVZ0eE1yMWlvS3BmNUlSbU5SZktnTmtjVmgxX2RHUnBPV0ZJNE5lemc0Nm43WEd2SjRESHRzclluaEdwMU8xbEV2aEVNUVdXQkstcVRoWmJJdmdWeFhrYVlnNmRlVXUzREt4Z1FZaEdELXFLekoyVi1Db0NxVzB6eGVBV182VkRBYl9BRFdvdWt2R2VwX0lmWjZGUTRReE9oQVJaWGI0NUx3VlNfVnNWWUpUdUFOcTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOeEc0UzI4cVNPMm9OMi1UQ2o0M214NmYwZDZCUEpnR2xtTTkyVXJhYk5qYTcwemdHZ2Y5M3lxNEFESGNtMEh1TVF0U0xCcVNtVmlXc3RXOVNwOWNvS2FraHVLOGhEbk93LWpwUWZKN0VBby1lOWRNR0R3dHdlYndaSWxJb0NaV19VSkU4QzU3eDNsOUhCQ1h0THhXMmhweHhMdGc?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxONDFUU01fLTEwb0Y1N2d1M3ZTUldYOXFVQ3lKQkd5cFo4UWdpd2k0aXQzV1k2emxpXzdMZU9BS3dqSDVuS2gzbzhFbWlZNFpSMTZCdXQ3YVJHM05QYVFaUk5XSmpjUXVzREJ2TnA5dFpaUzhtRzZxOEo3MVZ3bS1ldHVVVE5zTFhJekdsN0t3?oc=5", "source_name": "Market source", "published_at": "2026-01-18T08:00:00+00:00", "published_display": "18 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 63, "sentiment_summary": {"positive": 9, "negative": 7, "neutral": 47, "score": 51, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 24.5, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 7.5, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 24.89, "latest_week": "2026-07-17", "one_week_move": -10.7, "four_week_move": 3.3, "twelve_week_move": 17.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 19.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.3704, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.7% over one week, +3.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 9}, {"label": "Moomoo", "count": 3}, {"label": "Investing.com Nigeria", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Bitget", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.7% over one week, +3.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?"}], "updated_at": "2026-07-24T16:54:08.333442+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}